Cardia Bioplastics secures US patent protection for its foam products and processes

Image credit: SECOS Group ASX release

SECOS Group Limited has announced that Cardia Bioplastics, its wholly owned subsidiary, has secured patent protection of its foam products and processes from the US Patent and Trademark Office.

Image credit: SECOS Group ASX release
Image credit: SECOS Group ASX release

The new patent – which was granted for Cardia’s Biohybrid resin formulations tailored to protective packaging foam applications – expands  the company’s growing intellectual property portfolio of 11 patent families, with 20 patents so far granted in USA, Europe, Australia, China, Japan, New Zealand and South Africa.

Commenting on the news, Cardia Bioplastic’s CEO, Dr Frank Glatz, said the patent protects the composition and manufacturing process invented by the company’s R&D team.

“This marks an important milestone for Cardia Bioplastics as granted patents further support the technical differentiation of our Cardia Biohybrid and Compostable product offering and protect the intellectual property of the company,” Mr Glatz added.

“Cardia is collaborating with leading global brand owners to reduce the environmental impact of their packaging. Cardia’s Biohybrid technology enables them to reduce the carbon footprint and the use of less oil in their packaging with an environmental benefit whilst maintaining product performance. Cardia’s strong patent position and freedom to operate is a critical requirement for these large global brand owners.”

SECOS Group Chairman, Mr Richard Tegoni, said the continual expansion of Cardia’s patent portfolio validated the company’s technical capabilities and unique formulations.

“Protecting Cardia’s intellectual property is a high priority as it supports our businesses long-term growth strategy of creating new Compostable and Biohybrid resins that meet the needs of the growing market for resins and finished products,” Mr Tegoni concluded.

SECOS was formed in April 2015 by the merger of the business operations of Cardia Bioplastics Limited and the Stellar Films Group of companies. The Group has manufacturing plants in Australia, Malaysia and China and a global sales and distribution network in 27 countries.